Lee's Pharmaceutical Holdings Limited Stock OTC Markets
Stocks
LPCUF
KYG5438W1116
Pharmaceuticals
OTC Markets Traded|
Delayed
OTC Markets
09:30:00 2025-11-20 EST
|
5-day change | 1st Jan Change | ||
| 0.1903 USD | +1.12% |
|
-.--% | - |
| 09-10 | Lee's Pharma Licenses Cancer Drug OC-3 From 1cBio; Shares Plummet 4% | MT |
| 08-31 | Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 698M 88.95M 78.06M 73.72M 67.18M 126M 8.53B 127M 882M 342M 4.36B 334M 327M 14B | P/E 2024 |
8.98x | P/E 2025 | 9.74x |
|---|---|---|---|---|---|
| Enterprise Value | 658M 83.9M 73.62M 69.53M 63.37M 119M 8.04B 119M 832M 322M 4.11B 315M 308M 13.2B | EV / Sales 2024 |
0.6x | EV / Sales 2025 | 0.6x |
| Free-Float |
50.73% | Yield 2024 |
3.17% | Yield 2025 | 2.96% |
| 1 day | +1.12% |
| 1 year | 0.19 |  | 0.19 |
| 3 years | 0.19 | | 0.19 |
| 5 years | 0 | | 0.35 |
| 10 years | 0 | | 0.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 73 | 1997-03-31 | |
Yiu Ming Chow
DFI | Director of Finance/CFO | 53 | 2014-10-06 |
Sze Ka Wong
CTO | Chief Tech/Sci/R&D Officer | 44 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Siu Fong Lee
CHM | Chairman | 70 | 2010-04-04 |
| Director/Board Member | 73 | 2001-11-30 | |
Xiao Yi Li
BRD | Director/Board Member | 63 | 2003-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.12% | -.--% | - | - | 92.35M | |
| +0.28% | +2.65% | +65.61% | +114.28% | 1,053B | |
| +0.30% | +0.41% | +52.53% | +69.16% | 652B | |
| -0.26% | +0.06% | +20.86% | +70.79% | 468B | |
| -0.85% | +0.98% | +41.29% | +44.38% | 351B | |
| +0.71% | +4.08% | +22.24% | +29.51% | 273B | |
| +1.23% | +0.42% | +14.57% | +12.13% | 254B | |
| +1.26% | +7.54% | +52.93% | +55.40% | 220B | |
| +0.80% | -0.02% | +35.22% | +100.56% | 186B | |
| 0.00% | -10.14% | -29.94% | -60.30% | 170B | |
| Average | +0.37% | +0.30% | +30.59% | +48.44% | 403.04B | |
| Weighted average by Cap. | +0.22% | +1.00% | +41.48% | +67.80% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 1.4B 178M 157M 148M 135M 252M 17.11B 254M 1.77B 686M 8.74B 670M 656M 28.09B | 1.44B 183M 161M 152M 138M 259M 17.55B 261M 1.82B 703M 8.96B 687M 672M 28.81B |
| Net income | 93.1M 11.87M 10.41M 9.84M 8.96M 16.78M 1.14B 16.9M 118M 45.59M 581M 44.56M 43.6M 1.87B | 91.94M 11.72M 10.28M 9.71M 8.85M 16.57M 1.12B 16.69M 116M 45.02M 574M 44.01M 43.05M 1.84B |
| Net Debt | 10.45M 1.33M 1.17M 1.1M 1.01M 1.88M 128M 1.9M 13.22M 5.12M 65.25M 5M 4.9M 210M | -39.63M -5.05M -4.43M -4.19M -3.82M -7.14M -484M -7.19M -50.1M -19.41M -247M -18.97M -18.56M -795M |
Employees
1,137
Sector
Pharmaceuticals
Calendar
Net sales - Rate of surprise
- Stock Market
- Stocks
- 950 Stock
- LPCUF Stock
Select your edition
All financial news and data tailored to specific country editions
